{"id":"myl-1701p-a-proposed-biosimilar-to-eylea","safety":{"commonSideEffects":[{"rate":null,"effect":"Conjunctival hemorrhage"},{"rate":null,"effect":"Eye pain"},{"rate":null,"effect":"Floaters"},{"rate":null,"effect":"Intraocular pressure elevation"},{"rate":null,"effect":"Endophthalmitis"}]},"_chembl":{"chemblId":"CHEMBL6034845","moleculeType":null,"molecularWeight":"1138.26"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a biosimilar to Eylea (aflibercept), MYL-1701P is a recombinant fusion protein that acts as a VEGF trap, sequestering VEGF-A, VEGF-B, and PlGF to prevent their interaction with endothelial growth factor receptors. This mechanism reduces abnormal blood vessel growth and vascular permeability in retinal diseases. The biosimilar is designed to have comparable efficacy and safety to the reference product in treating neovascular age-related macular degeneration and other retinal conditions.","oneSentence":"MYL-1701P is a biosimilar to aflibercept that binds vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to inhibit pathological neovascularization in the eye.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:22:22.348Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neovascular (wet) age-related macular degeneration"},{"name":"Retinal vein occlusion"},{"name":"Diabetic macular edema"}]},"trialDetails":[{"nctId":"NCT04674800","phase":"PHASE3","title":"Extension Study of MYL-1701P-3001 for Safety and Efficacy","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2020-11-23","conditions":"Diabetic Macular Edema","enrollment":52}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MYL-1701P, a proposed biosimilar to Eylea","genericName":"MYL-1701P, a proposed biosimilar to Eylea","companyName":"Mylan Pharmaceuticals Inc","companyId":"mylan-pharmaceuticals-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"MYL-1701P is a biosimilar to aflibercept that binds vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to inhibit pathological neovascularization in the eye. Used for Neovascular (wet) age-related macular degeneration, Retinal vein occlusion, Diabetic macular edema.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}